Serum autoantibodies in SLE-patients
| Antibody | Seropositivity n (%) CA or CC | AA | P value | OR (95% CI) |
| IgM aCL | 10 (19%) | 96 (22%) | ns | 0.85 (0.44 to 1.65) |
| IgG aCL | 11 (20%) | 78 (18%) | ns | 1.20 (0.63 to 2.29) |
| IgG anti-β2GPI | 9 (17%) | 91 (21%) | ns | 0.84 (0.43 to 1.68) |
| IgG PT | 4 (7%) | 56 (13%) | ns | 0.69 (0.27 to 1.73) |
| IgG anti-CCP | 4 (24%) | 8 (4%) | 1.39×10−2 | 4.56 (1.36 to 15.26) |
| IgG anti-CAP | 2 (12%) | 12 (7%) | ns | 1.60 (0.37 to 6.92) |
| ANA | 115 (96%) | 850 (99%) | ns | 0.40 (0.16 to 1.04) |
| anti-dsDNA | 53 (61%) | 421 (62%) | ns | 1.50 (0.17 to 13.10) |
| anti-Sm | 14 (16%) | 79 (12%) | ns | 0.98 (0.64 to 1.50) |
Serum anti-CL, anti-β2-GPI and anti-PT were analysed in 490 patients (54 CA/CC and 436 AA) where all have data for anti-CL IgG and anti-prothrombin, 488 patients (54 CA/CC and 434 AA) have data for anti-CL IgM and 489 patients (53 CA/CC and 436 AA) have anti-β2-GP1 data. Serum anti-CCP and anti-CAP were measured by ELISA in 195 patients (17 CA/CC and 178 AA). ANA, anti-dsDNA and anti-Sm were measured according to the diagnosis criteria of American College of Rheumatology. Data for ANA were available from 982 patients (120 CA/CC and 862 AA) and anti-dsDNA and anti-Sm data was available from 761 patients (87 CA/CC and 674 AA). CA or CC indicate rs2230926 risk allele.
ANA, anti-nuclear antibodies; anti-Sm, anti-Smith antibodies; β2-GPI, β2 glycoprotein-I; CCP, cyclic citrullinated peptide (pos≥25 U/mL); CL, cardiolipin; dsDNA, double-stranded DNA; ns, non-significant; PT, prothrombin; SLE, systemic lupus erythematosus.